Biotech Micro-Cap IR Services
AxonIR is the AI-native investor relations firm for NYSE/NASDAQ-listed biotech micro-caps under $500M market cap. We score every clinical-update 8-K, 10-Q, and 10-K against biotech-specific peer benchmarks, with calibration for clinical-stage vs commercial-stage companies.
Why biotech disclosure language is different
Biotech disclosure is the most algorithmically-scrutinized vocabulary in the public-company universe. Every clinical-trial-update 8-K is parsed within milliseconds for endpoint-language clarity, statistical-significance phrasing, safety-event description tone, and forward-looking-statement precision. Algorithmic systems are calibrated against the historical correlation between specific phrasing patterns and post-announcement stock performance — phrases like "the primary endpoint was met" score very differently from "showed clinical activity," even when the underlying data is similar. Biotech micro-caps that do not score their clinical-update 8-Ks before wire distribution are flying blind: their competitor companies routinely use AxonIR-equivalent NLP optimization, and the readability gap is measurable in post-update trading volatility. AxonIR's biotech sector overlay extends Loughran-McDonald with a clinical-trial-language layer covering FDA terminology, endpoint-classification language, and safety-event vocabulary. For 10-Q and 10-K scoring, the engine emphasizes risk-factor weighting because biotech risk-factor sections are read by both algos and FDA-related searches.
Sector-specific algo readability benchmarks
Biotech algo readability benchmarks split sharply between clinical-stage and commercial-stage companies. Clinical-stage biotechs (no approved products) tend to score lower on Fog index because their disclosure is dominated by trial-update narrative which is inherently complex. Commercial-stage biotechs (one or more approved products) score higher because revenue-recognition disclosure pulls the average. Sub-segments include oncology, rare disease, gene therapy, and CNS — each with distinct vocabulary patterns. AxonIR maintains peer benchmarks at the sub-segment level.
Peer benchmarking
Biotech peer benchmarking is calibrated against the sub-segment peer set (e.g., oncology clinical-stage micro-caps). AxonIR uses an aggregated peer set (typically 20–40 comparables) and reports each client's percentile against that set. Individual peer scores are not shared. Biotech micro-caps engaging AxonIR receive their sub-segment percentile with each quarterly review.
Recommended tier for biotech pubcos
Scale ($2,500/mo) most popular for clinical-stage; Enterprise ($4,000/mo) for commercial-stage
All tiers include sector-calibrated NLP scoring, quarterly peer benchmarking, and unlimited 8-K pre-publication review.
Get Free Algo Score